Okayama University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Okayama Japan (1870)

Organization Overview

First Clinical Trial
2004
NCT00106158
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Assistant Professor, Endocrinological Center, Okayama University Hospital | Department of Anesthesiology and Intensive Care, Okayama University Hospital | Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | Dept. of Immunology, Okayama University Schhol of Medicine and Dentistry | Graduate School of Health Sciences, Okayama University | Graduate School of Medicine and Dentistry, Okayama University | Okayama University | Okayama University Graudate School of Medicine | Okayama University School of Medicine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 3)

Cardiomyopathies (Phase 1)

Cardiomyopathy, Dilated (Phase 1)

Chest Pain (Phase 2)

Coronary Artery Disease (Phase 2)

Depression (Phase 4)

Heart Diseases (Phase 2)

Hypoplastic Left Heart Syndrome (Phase 2)

Infarction (Phase 2)

Ischemia (Phase 2)

Leukemia (Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, T-Cell (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Motor Neuron Disease (Phase 3)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 2)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 15